V ein grafts are the most common conduit used for surgical revascularization procedures. However, these grafts are susceptible to the development of intimal hyperplasia and accelerated atherosclerosis, which result in failure rates of 20% to 40% at 5 years. 1, 2 Intimal hyperplasia is a chronic structural lesion that develops after vein graft implantation and leads to luminal stenosis and occlusion. 3 It may be defined as abnormal migration and proliferation of vascular smooth muscle cells with associated deposition of extracellular connective tissue matrix. The development of intimal hyperplasia in experimental vein grafts is also associated with increased or novel expression of G proteins (␣ and ␤␥ subunits) in vivo, which occurs simultaneously with phenotypically altered contractile function. 4 Experimental vein grafts possess increased concentrations of the G protein ␣ S , ␣ i2 , ␣ q , and ␤ subunits. 4 ,5 G ␣i3 is detectable in vein grafts that display intimal hyperplasia but not in the native jugular veins. 4, 5 Regarding the physiology of vein grafts, contractile responses become sensitive to pertussis toxin (PTx), which differs from the PTx-insensitive contractile response in native veins. 4 PTx ADP ribosylates the G i /G o ␣ subunits, causing ablation of signaling. 6 Thus, G proteins appear to play a critical role in the phenotypical alterations associated with vein grafts and intimal hyperplasia. The signaling mechanisms triggering the proliferation and migration of vascular smooth muscle cells are not well understood, but G proteins could be involved because several growth factors that induce mitogenesis act through membrane-embedded, G protein-coupled receptors. On stimulation, G proteins dissociate to the G ␣ and G ␤␥ subunits, which can both lead to cellular signaling events. 6, 7 Several G protein-coupled mitogens, acting primarily through PTxsensitive G proteins, have been shown to specifically trigger intracellular signaling events via G ␤␥ , leading to proliferation through activation of p21 ras (ras) and subsequent activation of the p42 and p44 mitogen-activated protein (MAP) kinases. 8 The ␤-adrenergic receptor kinase 1 (␤ARK-1) is a G ␤␥ -dependent cytosolic enzyme that phosphorylates its activated receptor substrate after translocation to the cell membrane and binding to the membrane-anchored ␤␥ subunits. 9 A peptide encoded by the carboxyl terminus of ␤ARK-1 (␤ARK CT ) contains the specific ␤␥-binding domain of the enzyme. 10 It was previously shown that when cells are transfected with a ␤ARK CT plasmid or when peptides con-taining the G ␤␥ -binding domain of ␤ARK CT are introduced into the cells, several G ␤␥ -dependent processes are inhibited, including activation of ras and MAP kinase by several mitogens. 8, 11 In addition, it has also been demonstrated that the peptide encoded by ␤ARK CT is specific for G ␤␥ and does not directly alter G ␣ -mediated responses. 8, 11 We hypothesized that blockade of the G ␤␥ subunit would result in a reduction in intimal hyperplasia. This study examined the effect of ␤ARK CT on the formation of vein graft intimal hyperplasia and phenotypical functional alterations.
Methods

Experimental Design
Forty New Zealand White rabbits underwent carotid interposition vein bypass grafting. Before grafting, veins were incubated in heparinized Ringer's lactate (controls, nϭ18) or plasmid solutions containing either ␤ARK CT (nϭ14, 190 g/mL) or empty plasmid DNA (plasmid nϭ8, 190 g/mL) for 30 minutes at 37°C. These concentrations were shown to produce efficient transfection in vitro. Twenty-four vein grafts (controls nϭ10, plasmid nϭ6, and ␤ARK CT nϭ8) were harvested at 28 days by perfusion fixation. Intimal and medial dimensions of vein grafts were calculated by video morphometry. Sections were taken for scanning and transmission electron microscopy. Ten vein grafts (nϭ5, control and ␤ARK CT ) were analyzed for in vitro contractile responses to norepinephrine and serotonin in the presence and absence of PTx to categorize G protein-receptor coupling. Six vein grafts (nϭ3, control and ␤ARK CT ) were harvested at 3 days for ␤ARK CT 
Transgene Constructs
Gene transfer to the experimental vein grafts was done using our previously described plasmid, which contains cDNA encoding the last 194 amino acid residues (Met-Gly 495 -Leu 689 ) of bovine ␤ARK CT (pRK-␤ARK CT ). 8, 10 This peptide contains the experimentally determined (Gln 546 -Ser 670 ) G ␤␥ -binding domain. The empty pRK5 plasmid was used as the negative control as previously described. 8, 11 Largescale plasmid preparations of pRK5 and pRK-␤ARK CT were purified on Qiagen columns (Qiagen, Inc) before vein graft gene transfer.
Analysis of ␤ARK CT Transgene Expression
Three-day vein grafts were used for analysis of specific transgene expression. ␤ARK CT mRNA expression was determined by standard methods of RT-PCR 14 with an RT-PCR kit using TaqPlus DNA polymerase (Stratagene, Inc). Total RNA was first isolated using the single-step reagent RNAzol (Biotecx, Inc) 15 and treated with DNase I to eliminate any possible plasmid contamination. A ␤ARK CT primer set was used to specifically amplify ␤ARK CT mRNA. The primers were as follows: sense primer (corresponding to the start of ␤ARK CT ), 5Ј-GAATTCGCCGCCACCATGGG-3Ј; and antisense primer (corresponding to the ␤ globin-untranslated region linked to the end of the ␤ARK CT cDNA 11 ), 5Ј-GGAACAAAGGAACCTTTAATAG-3Ј. This primer set amplifies a 670-bp fragment corresponding to ␤ARK CT mRNA.
Operative Procedure
Anesthesia was induced and maintained with subcutaneously injected ketamine hydrochloride (60 mg/kg, Ketaset, Bristol Laboratories) and xylazine (6 mg/kg, Anased, Lloyd Laboratories). Antibiotic prophylaxis with 30 000 IU/kg of benzathine and procaine penicillin (Durapen, Vedco, Inc) was given intramuscularly at the time of induction. Surgery was performed using an operating microscope (JKH 1402, Edward Weck, Inc) under sterile conditions. After exposure through a midline longitudinal neck incision, the right external jugular vein was identified, its branches were coagulated by diathermy at a distance from the vein to minimize injury, and the vein was then excised. After excision, the vein was incubated in a heparinized Ringer's lactate solution (5 IU/mL, heparin, ElkinsSinn, Inc) containing either ␤ARK CT (nϭ14, 190 g/mL) or empty plasmid DNA (plasmid nϭ8, 190 g/mL) for 30 minutes at 37°C. Ex vivo, a cannula was placed atraumatically into a branch of the jugular vein, and the incubation solution was introduced once into the lumen of the vein without developing any distension pressure to ensure luminal and adventitial exposure. The right common carotid artery was identified and dissected, and both proximal and distal control was obtained. Heparin (200 IU/kg) was administered intravenously. A proximal longitudinal arteriotomy was made, and one end of the reversed jugular vein was anastomosed to the artery in an end-to-side manner using a continuous 10-0 microvascular monofilament nylon suture (Ethilon, Ethicon, Inc, Somerville, NJ). The distal anastomosis was performed in a similar manner. Throughout the procedure, care was taken to avoid unnecessary instrumentation of the vein graft. The right common carotid artery was ligated and divided between the two anastomoses with 4-0 silk sutures, and the wound was closed in layers.
Morphology
Vein grafts were harvested 28 days after surgery. After isolation and systemic heparinization (200 IU/kg IV), the vein grafts were perfusion fixed in situ at 80 mm Hg with an initial infusion of HBSS (Gibco Laboratories, Life Technologies, Inc), followed by 2% glutaraldehyde made up in 0.1 mmol/L cacodylate buffer (pH 7.2) supplemented with 0.1 mmol/L sucrose to give an osmolality of Ϸ300 mOsm. After 60 minutes, the specimen was removed and immersed in the glutaraldehyde fixative for an additional 24 hours. Cross sections from the middle portion of the vein graft were processed for light microscopy. With the use of standard histological procedures, each specimen was stained with a modified Masson's trichrome and Verhoeff's elastic tissue stain and dimensional analysis was performed by video morphometry (Innovision 150, American Innovision, Inc). The intima and media were delineated by identification of the demarcation between the crisscross orientation of the intimal hyperplastic smooth muscle cells and circular smooth muscle cells of the media, and the outer limit of the media was defined by the interface between the circular smooth muscle cells of the media and the connective tissue of the adventitia. The thickness of each layer was also determined. A ratio of the intimal and medial areas (intimal area/[intimalϩmedial areas]) and an index of luminal diameter to cross-sectional wall thickness (luminal diameter/crosssectional wall thickness) were calculated.
In Vitro Contractile Studies
For these studies, the animals were anesthetized, the original incision was reopened, and the jugular vein and vein graft were isolated. The middle part of each vessel was sectioned in situ into four 5-mm segments and excised. These rings were suspended immediately from 2 stainless steel hooks in 5-mL organ baths containing oxygenated Krebs solution (122 mmol/L NaCl, 4.7 mmol/L KCl, 1.2 mmol/L MgCl 2 , 2.5 mmol/L CaCl 2 , 15.4 mmol/L NaHCO 3 , 1.2 mmol/L KH 2 PO 4 , and 5.5 mmol/L glucose, maintained at 37°C and bubbled with a mixture of 95% O 2 and 5% CO 2 ). One hook was fixed to the bottom of the bath, and the other was connected to a force transducer (Myograph F-60, Narco Bio-Systems). The isometric responses of the tissue were recorded on a multichannel polygraph (Physiograph Mk111-S, Narco Bio-Systems). The tissues were then placed under 0.5 g of tension and allowed to equilibrate in physiological Krebs solution for 1 hour. During the equilibration period, the Krebs solution was replaced every 15 minutes. After equilibration, the resting tension was adjusted in 0.25-g increments from 0.25 to 2.5 g, and the maximal response to a modified oxygenated Krebs solution (60 mmol/L KCl, 66.7 mmol/L NaCl, 1.2 mmol/L MgCl 2 , 2.5 mmol/L CaCl 2 , 15.4 mmol/L NaHCO 3 , 1.2 mmol/L KH 2 PO 4 , and 5.5 mmol/L glucose) was measured at each resting tension to establish a length-tension relation. On the basis of these results, the optimal resting tension for each ring (the tension at which the response to the modified Krebs solution was maximal) was determined, and the ring was set at this tension for subsequent studies. Norepinephrine (10 Ϫ9 to 10 Ϫ4 mol/L) was added cumulatively in half-molar increments, and the isometric tension developed by the tissue was measured. After washout and reequilibration, dose-response curves were obtained for serotonin (10 Ϫ9 to 10 Ϫ4 mol/L). The responses to each agonist were assessed in the presence and absence of PTx (100 ng/mL preincubated for 60 minutes). 4 All compounds were obtained from Sigma Chemical Company.
Data and Statistical Analyses
The EC 50 value, the concentration for the half-maximal response, for each agonist in each ring was calculated by logistic analysis and is expressed as Ϫlog 10 [EC 50 ]. 16 All data are presented as meanϮSEM, and statistical differences between groups were tested by ANOVA with post hoc Tukey-Kramer multiple-comparison tests (functional studies) and with a Kruskal-Wallis nonparametric ANOVA with post hoc Dunn's multiple-comparison tests (morphometric data).
Results
Transgene Expression
Successful transfection of the vein grafts was demonstrable 3 days after surgery. ␤ARK CT mRNA was specifically amplified from DNase I-treated total RNA using RT-PCR from vein grafts treated with pRK-␤ARK CT , whereas control grafts treated with the empty pRK5 plasmid showed no transgene expression at 3 days (Figure 1) . No pRK5 and pRK-␤ARK CT RNA was detectable at 5 and 7 days, suggesting transient expression of the vector (data not shown). Because the amount of tissue available was small, protein immunoblotting for ␤ARK CT peptide expression was not possible.
Intimal Hyperplasia
All animals survived to 28 days, and all grafts were patent at harvest. The jugular vein of the rabbit consists of a single layer of endothelial cells and 1 or 2 layers of smooth muscle cells in a loose, connective tissue matrix (histological data not shown). Microscopically, the luminal surfaces of the vein grafts from each group were covered by a layer of intact endothelial cells, beneath which lay a hyperplastic intima with the smooth muscle cells arranged in a crisscross pattern with little extracellular matrix (Figure 2 ). The medial smooth muscle cells in the grafts from each group appeared slender, were arranged in a circular pattern, and contained a greater amount of extracellular matrix, suggestive of medial hypertrophy. At 28 days, there was a significant (36%) reduction in intimal thickness in ␤ARK CT vein grafts (45Ϯ4 m, nϭ8) compared with either plasmid (69Ϯ3 m, nϭ6) or control (70Ϯ4 m, nϭ10) vein grafts without a significant change in medial thickness. Results of dimensional analysis of the control and treated groups are shown in Table 1 . There was a 52% decrease in intimal area (Table 1) , whereas the medial area was unchanged in the ␤ARK CT -treated vein grafts compared with the plasmid-treated grafts ( Table 1 ). The intimal ratio was significantly reduced in the ␤ARK CT vein 
Contractile Function of Experimental Vein Grafts
Control and ␤ARK CT -treated vein grafts responded with concentration-dependent contractions to the agonists norepinephrine and serotonin. In the presence of PTx at concentrations sufficient to produce 100% ADP ribosylation of G proteins, 4 the contractile responses in control vein grafts to norepinephrine (PϽ0.01) and serotonin (PϽ0.01) were significantly reduced compared with untreated control vein grafts (Table 2 ). This is the typical functional alteration seen in experimental vein grafts, because native veins do not have a PTx-sensitive component in their contractile responses to these G protein-coupled agonists. In contrast, the responses of the ␤ARK CT -treated vein grafts to norepinephrine and serotonin were unchanged in the presence of PTx, indicating the loss of a G ␣i component ( Table 2 ).
Electron Microscopy of Vein Grafts
Scanning electron microscopy of both control vein grafts and vein grafts transfected with empty plasmid showed the luminal surface to be lined with sharply outlined endothelial Data are meanϮSEM. Contractile sensitivity is shown as Ϫlog EC 50 . *PϽ0.01 compared with corresponding vein graft not treated with PTx (ANOVA). There was no difference in the maximal contractile responses to the two agonists in the different preparations when they were normalized to their responses to the 60-mmol/L KCl solution.
cells with well-defined cell borders ( Figure 3A) . Occasional junctional stomata were noted. Transmission electron microscopy of these vein grafts confirmed the presence of wellformed endothelial cells, beneath which were well-developed smooth muscle cells of both contractile (cytoplasm predominantly filled with contractile filaments) and synthetic (cytoplasm filled with synthetic organelles) phenotypes in a loose, connective tissue matrix. No inflammatory cells or evidence of apoptosis was identified in these grafts. Scanning electron microscopy of vein grafts transfected with ␤ARK CT showed a similar picture for the control and plasmid-transfected vein grafts with well-preserved, normal-appearing endothelial cells with occasional stomata at their junctions on the luminal surface ( Figure 3B ). Transmission electron microscopy showed an ultrastructural pattern similar to that of the control and plasmid-transfected vein grafts.
Discussion
This study revealed 3 novel findings in the area of surgical and gene-transfer manipulations of vein grafts. First, we showed for the first time that plasmid DNA can be transiently transferred to an experimental vein graft. Second, we found that the transfection of a G ␤␥ inhibitor (␤ARK CT ) results in a significant in vivo biological effect (ie, reduction in intimal hyperplasia up to 28 days). Finally, ␤ARK CT transfection resulted in alterations in functional coupling of G ␣ subunits to vascular agonists.
There is considerable interest in modulating the development of vein graft intimal hyperplasia by molecular means. To date, transfection of vein grafts with adenovirus has been demonstrated to have limited efficacy. LeClerc et al 17 showed that ␤-galactosidase can be introduced into the endothelium of vein grafts at the time of operation but that the viral transfection is short-lived and is lost by 7 days. Chen et al 18 demonstrated that the vascular cell adhesion molecule can be transfected into porcine vein grafts at the time of implantation but, again, with limited duration of transfection. Mann et al 19 demonstrated that liposome-delivered antisense oligonucleotide can achieve effective delivery of anti-cyclin/cdck2, with a significant decease in intimal hyperplasia, but there was an increase in medial hypertrophy compared with controls. We have demonstrated that pluronic gel delivery of c-myb antisense oligonucleotide will decrease vein graft intimal hyperplasia without changing the medial response. 20 This study is the first to demonstrate plasmid transfection into a vein graft with a sustained biological effect. Efficient transfer of DNA was determined by ␤ARK CT mRNA amplification in 3-dayold vein grafts. Only the vein grafts treated with the ␤ARK CT plasmid showed transgene expression. DNase I was added to the isolated total RNA to eliminate any possibility of plasmid contamination.
Activation of both G protein-coupled and protein tyrosine kinase-coupled receptors results in a sequential cascade of phosphorylation reactions that converge at the MAP kinase step in the phosphorylation cascade. 7, [21] [22] [23] Intraoperative transfection of vein grafts with ␤ARK CT resulted in a 36% reduction in intimal hyperplasia at 28 days. The marked decrease in intimal hyperplasia appears to be the result of modulation of G protein signaling activity in the vein graft smooth muscle cells. These findings suggest that G ␤␥ is critical in the proliferation of smooth muscle cells required for intimal hyperplasia formation. This is a significant finding, because most of the attention is given to tyrosine kinase receptor-activating growth factors, such as platelet-derived growth factor, fibroblast growth factor, and insulin. However, in light of our findings, the role of activated G proteincoupled receptors, which subsequently leads to G ␤␥ -mediated mitogenesis, should be further defined. This hypothesis is supported by our previous findings that G i -coupled receptors, such as lysophosphatidic acid, ␣ 2 -adrenergic, and M2 muscarinic cholinergic receptors, activate the ras-MAP kinase pathway through G ␤␥ , whereas G ␣s -coupled and G ␣q -coupled receptors do not. 8, 24 In addition, we have also shown that a tyrosine kinase growth factor, insulin growth factor 1, can activate the ras-MAP kinase pathway through G ␤␥.
25 Other agents that can couple and activate G ␣i include thrombin and angiotensin II (both of which can also couple to G ␣q ). Both of these agents have been implicated in stimulating growth. We cannot directly state that G ␤␥ inhibits MAP kinase activity, because we have not been able, to date, to demonstrate significant MAP kinase activity at early time points in either control or transfected vein grafts. Thus, several candidate potential G protein-coupled receptors exist that might direct vein graft intimal hyperplasia and whose signaling would be inhibited by the ␤ARK CT .
One difference in our approach to inhibiting vascular smooth muscle proliferation is that it is targeted to a specific pathway. Approaches such as antisense oligonucleotides 18, 26 or herpesvirus thymidine kinase gene delivery are nonselective inhibitors of mitogenesis and may affect other cell types. 27 ␤ARK CT targets 1 common pathway that is apparently shared by several mitogens. Our findings suggest a critical role for G ␤␥ signaling in intimal hyperplasia.
Functional responses of vascular smooth muscle cells to vasoactive agonists may be representative of "stimulusresponse coupling" and may broadly define the status of many of the common extracellular signals, surface receptor systems, and intracellular regulatory mechanisms present. The increases in G proteins after vein grafting 4 are associated with the development of enhanced PTx-sensitive contractile responses that are known to be coupled to G␣ i proteins. 28, 29 Native veins do not have PTx-sensitive contractile responses. Although ␤ARK CT does not affect G ␣ -mediated events, intraoperative transfection with ␤ARK CT abolished the sensitivity of the contractile responses of the vein graft to PTx. This suggests that the contractile responses in the ␤ARK CT -transfected vein grafts are mediated predominantly by PTx-insensitive G ␣ subunits (ie, G ␣q , which is more like native veins). The mechanism of G protein-coupling change is not known, and additional experiments will be required to determine whether this is a property of specific G ␤␥ inhibition or another mechanism, possibly dealing with the loss of vascular smooth muscle "buildup." Nonetheless, our results indicate that transfection of vein grafts with a plasmid containing a G ␤␥ inhibitor produces a significant biological effect with the potential to have a large impact in the surgical vein graft arena.
